Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years.
about
Surveillance imaging in mantle cell lymphoma in first remission lacks clinical utility.Minimal residual disease in mantle cell lymphoma: are we ready for a personalized treatment approach?Minimal Residual Disease Assessment in Lymphoma: Methods and Applications.Past, Present, and Future of Rituximab-The World's First Oncology Monoclonal Antibody Therapy.Current overview and treatment of mantle cell lymphoma
P2860
Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Molecular Monitoring after Aut ...... Median Follow-Up of 8.5 Years.
@en
Molecular Monitoring after Aut ...... c Mantle Cell Lymphoma Studies
@nl
type
label
Molecular Monitoring after Aut ...... Median Follow-Up of 8.5 Years.
@en
Molecular Monitoring after Aut ...... c Mantle Cell Lymphoma Studies
@nl
prefLabel
Molecular Monitoring after Aut ...... Median Follow-Up of 8.5 Years.
@en
Molecular Monitoring after Aut ...... c Mantle Cell Lymphoma Studies
@nl
P2093
P50
P1476
Molecular Monitoring after Aut ...... Median Follow-Up of 8.5 Years
@en
P2093
Anna Laurell
Arne Kolstad
Christer Sundström
Christian Hartman Geisler
Christian W Eskelund
Elisabeth Ralfkiær
Erkki Elonen
Grete Fossum Lauritzsen
Hans Bentzen
P304
P356
10.1016/J.BBMT.2016.12.634
P577
2016-12-27T00:00:00Z